Tasonermin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Tasonermin: From Soft Tissue Sarcoma to Prostatic Urethra Urothelial Carcinoma
One-Sentence Summary
Tasonermin is a recombinant human TNF-alpha, with established clinical use limited to isolated limb perfusion for locally advanced soft tissue sarcoma and melanoma (EU-approved as Beromun). The TxGNN model predicts it may be effective for Prostatic Urethra Urothelial Carcinoma, but currently no clinical trials and no publications support this specific direction — the prediction rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Soft tissue sarcoma / melanoma (isolated limb perfusion; EU-approved as Beromun) |
| Predicted New Indication | Prostatic Urethra Urothelial Carcinoma |
| TxGNN Prediction Score | 99.81% |
| Evidence Level | L5 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Tasonermin is a recombinant human TNF-alpha. Its only established clinical use is regional isolated limb perfusion for locally advanced soft tissue sarcoma and melanoma of the extremities (approved in the EU as Beromun), where it selectively damages tumour vascular endothelium and enhances the penetration of co-administered chemotherapy.
TNF-alpha signalling has been described in the inflammatory and immune microenvironment of urothelial carcinoma in some literature, but there is no direct mechanistic evidence linking Tasonermin to prostatic urethra urothelial carcinoma specifically. The TxGNN high score most likely reflects broad “TNF-alpha–cancer” connectivity within the knowledge graph rather than a disease-specific mechanistic signal.
Furthermore, Tasonermin’s existing clinical experience is confined to regional/locoregional administration (isolated limb perfusion); there is no pharmacokinetic or safety basis established for systemic use in a urological tumour such as this. This prediction should therefore be regarded as a hypothesis-generating signal only, not as evidence of therapeutic potential.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
Tasonermin is currently not marketed in Denmark, and no marketing authorisations (national Laegemiddelstyrelsen or centralised EMA) are on file for this product.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy/biologic (recombinant TNF-alpha cytokine) — not a conventional cytotoxic chemotherapeutic |
| Myelosuppression Risk | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions |
| Emetogenicity Classification | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions |
| Monitoring Items | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions |
| Handling Protection | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions |
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is evidence level L5 — supported only by TxGNN’s knowledge-graph score, with zero clinical trials and zero publications identified for Tasonermin in prostatic urethra urothelial carcinoma. A blocking data gap also remains on Danish/EU label warnings and contraindications, which prevents any safety pre-assessment.
To proceed, the following is needed:
- TFDA/SmPC label warnings and contraindications (currently blocking — required before any safety pre-screening)
- Confirmed mechanism of action detail via DrugBank or primary literature
- Preclinical or case-level evidence connecting TNF-alpha activity to urothelial carcinoma subtypes before further evaluation
- Clarification on feasible route of administration, given Tasonermin’s current use is limited to regional isolated limb perfusion
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.